Benzinga November 1, 2021
This Company has its Sights Set of Transforming the Pharmaceutical Industry With its Efficient C1 Vaccine & Drug Manufacturing Technology

Wall Street September 8, 2021
The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI)

Wall Street August 31, 2021
Desperation on Variants Paints Path for Long-Term Vaccine Thesis (DYAI, MRNA, PFE, JNJ, NVAX, BNTX, AZN, SRNE)

Wall Street August 12, 2021
Moderna bounces back with spotlight on other vaccine stocks (MRNA, DYAI, NVAX, JNJ, AZN, BNTX, PFE)

Wall Street August 4, 2021
The Covid Vaccine Market is a Long Game in the Early Innings (BNTX, AZN, DYAI, NVAX, MRNA, PFE, JNJ)

Wall Street July 28, 2021
Dyadic Int’l (DYAI) Inks Deal Toward Potential Access to 40% of the World as Covid Vaccine Continues in Development

MarketWatch July 22, 2021
Delta Means Beta Testing Alpha Strategies in Biotech (NVAX, MRNA, DYAI, PFE, JNJ, BNTX, AZN, IBB)

USA Today Special Edition July 19, 2021
See page 61 for: Dyadic applies novel C1 vaccine manufacturing platform based on Thermothelomyces fungus to develop vaccines & drugs against the coronavirus and emerging variants
For pdf click HERE

MarketWatch July 13, 2021
Emerging Themes in the COVID-19 Vaccine Space (MRNA, PFE, DYAI, JNJ, NVAX, BNTX, AZN)

MarketWatch June 9, 2021
Dyadic International (NASDAQ: DYAI): A Unique Approach to World Vaccination (DYAI, AZN, MRNA, NVAX, PFE, JNJ, BNTX)

GENEDGE June 8, 2021
Off Message:  Dyadic Fights Covid-19 with a Fungus

MarketWatch June 2, 2021
The Vaccine Investment Hypothesis, and What’s Next (AZN, JNJ, DYAI, BNTX)

MarketWatch May 26, 2021
Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

StreetInsider.com May 20, 2021
Could Dyadic International (DYAI) be a Dark Horse Vaccine MVP

Wall Street May 12, 2021
DYAI’s C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity

Elsevier Biologicals April 2021
Can a fungal platform be faster and cheaper than other platforms, enabling many cheaper and quicker therapeutics? Joris Vandeputte responded that the ZAPI experience shows that the fungal C1 system is a high-performance system, which can produce high quantities of apparently excellent antigens, in the appropriate conformation, and well glycosylated, which has been confirmed in animal models. So, this is one of the platforms that should be further explored in the near future.

MarketWatch April 28, 2021
Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYAI)

Journal Transcript April 20, 2021
DYAI in Focus: Upstart Vaccine Maker Says has Faster Way to Vaccinate the World (AZN, MRNA, NVAX, PFE, JNJ, BNTX)

StreetInsider.com April 9, 2021
Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: NVAX)

MarketWatch April 1, 2021
How Dyadic International Inc (NASDAQ: DYAI) Fits into the Vaccine 2.0 Gold Rush (NASDAQ: BNTX) (NYSE: JNJ) (NASDAQ: MRNA) (NYSE: PFE)

StreetInsider.com March 30, 2021
Is Dyadic International Inc. (NASDAQ: DYAI) the Key to Scaling Up Global Access to a Viable Covid-19 Vaccine?  (NASDAQ: NVAX) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: AZN)

Innovative Medicines Initiative March 24, 2021
A recipe for the next disaster: a new, pan-virus methodology for ramping up vaccine production
ZAPI have put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis

FinancialNewsMedia.com March 23, 2021
Covid-19 Pandemic Still Fueling Need for Increased Supplies & New Technology in PPE Markets